CVS Caremark updates formularies to prefer lower-cost biosimilars, cutting costs for patients starting July 2026.

CVS Caremark will update its commercial formularies effective July 1, 2026, to prefer FDA-approved interchangeable biosimilars over certain brand-name drugs, including switching from Stelara to biosimilars Pyzchiva and Yesintek. This change aims to reduce drug costs for clients and members, often resulting in $0 out-of-pocket expenses for patients. The update expands biosimilar coverage in specialty areas like multiple sclerosis and rare blood disorders, supporting affordability and access while maintaining clinical quality. CVS Caremark will provide communication and support to ensure a smooth transition for all stakeholders.